Ana Benzaquén

5PUBLICATIONS
46CO-AUTHORS
Haematological tumoursRadiation therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 12, 2026
Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.

Marta Peña, Lorenzo Lazzari, Diego F Martínez

|Apr 02, 2025
Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC.

M Peña, D F Martinez, A Paviglianiti

|Dec 11, 2024
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.

Virginia Escamilla-Gómez, Valentín García Gutiérrez, Patricia Alcalde-Mellado

|Nov 03, 2023
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy.

Ana Benzaquén, Estela Giménez, Gloria Iacoboni

|Oct 24, 2023
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.

Gloria Iacoboni, Víctor Navarro, Ana África Martín-López

Pageof 1

Frequent Collaborators

2 joint publications

Marta Peña

2 joint publications

Jaime Sanz

2 joint publications

Carlos Solano

2 joint publications

Juan Montoro